Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

1.6K
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
1.6K
Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

Aortic Regurgitation II: Clinical Features and Diagnostic Tests

1.2K
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
1.2K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

650
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same author

Intersaphenous veins in a population with a high prevalence of chronic venous insufficiency.

Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft·2026
Same author

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Orphanet journal of rare diseases·2026
Same author

Evaluation of the severity of right-to-left shunt in patent foramen ovale patients after systemic embolism (MEASURE-PFO study).

Kardiologia polska·2026
Same author

Expert opinion on facilitating intrafamily communication in rare diseases-Lessons from Fabry disease.

Genetics in medicine open·2026
Same author

A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease.

Molecular genetics and metabolism·2026
Same journal

Silent growth of multiple giant coronary artery aneurysms in eosinophilic granulomatosis with polyangiitis.

European heart journal·2026
Same journal

Clinical flaws in the breast cancer ADAM10 and atrial fibrillation study.

European heart journal·2026
Same journal

Cardiac MRI of myocardial iron deposition in hereditary aceruloplasminaemia.

European heart journal·2026
Same journal

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same journal

Improving individual lifetime cardiovascular disease risk estimation to optimize secondary prevention.

European heart journal·2026
Same journal

Differences and similarities of the genetic architectures of blood pressure and heart rate in children and adults.

European heart journal·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

4.6K

Aortic remodelling in Fabry disease.

Frédéric Barbey1, Salah D Qanadli, Christoph Juli

  • 1Department of Transplantation, Faculty of Medicine and Biology, University Hospital, Lausanne, Switzerland. frederic.barbey@chuv.ch

European Heart Journal
|October 24, 2009
PubMed
Summary
This summary is machine-generated.

Fabry disease (FD) can cause thoracic aortic dilation, particularly in males, affecting the aortic sinus. Regular monitoring for aortic dilation is crucial for patients with Fabry disease.

More Related Videos

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.6K

Related Experiment Videos

Last Updated: May 5, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

4.6K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

2.5K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.6K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Vascular Biology

Background:

  • Fabry disease (FD) is a rare genetic disorder with known cardiac manifestations.
  • The involvement of the thoracic aorta in FD has been less extensively studied.
  • Understanding vascular complications is key to managing FD patients.

Purpose of the Study:

  • To investigate the prevalence and characteristics of thoracic aortic dilation in patients diagnosed with Fabry disease.
  • To assess potential differences in aortic involvement between males and females with FD.
  • To determine if aortic dilation correlates with known cardiovascular risk factors in this population.

Main Methods:

  • A cohort of 106 patients with confirmed Fabry disease was recruited from three European centers.
  • Thoracic aortic dimensions were measured at the sinus of Valsalva, ascending aorta, and descending aorta.
  • Imaging techniques included echocardiography and cardiovascular magnetic resonance imaging.

Main Results:

  • Thoracic aortic dilation was observed at the sinus of Valsalva in 32.7% of males and 5.6% of females with FD.
  • Aortic aneurysms were identified in 9.6% of males and 1.9% of females.
  • No dilation was found in the descending aorta, and no correlation was observed between aortic sinus diameter and cardiovascular risk factors.

Conclusions:

  • Fabry disease should be recognized as a condition impacting the arterial vasculature, including the thoracic aorta.
  • Patients with Fabry disease require vigilant monitoring for aortic dilation, its progression, and potential complications.
  • Early detection and management of aortic abnormalities are essential in the comprehensive care of FD patients.